An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
← catalyst calendarNCT06951217 · readout in 1,960 d
Sponsored by Avalyn Pharma Inc. (industry) · AVLN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
340estimated
Sites
68
Countries
Argentina, Australia, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-17 | actual | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Progressive Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Intervention
- Combination product: AP01
Primary outcome
what the primary-completion date above is the date OFTo evaluate the long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications (AP01).
measured Through end of study; average of 6 years
Permalink · AVLN's whole pipeline · Catalyst calendar · Every registered study · What changed